Home / Guides / Retatrutide vs. tirzepatide
What the trials show. What’s legal now.
Retatrutide vs. tirzepatide: how the trial results compare, and what you can get now
By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD · Updated
No head-to-head result yet: as of November 1, 2026, Lilly hasn’t reported one, and TRIUMPH-5, its trial against tirzepatide, is listed through December 2026 (checked October 25, 2026). Retatrutide isn’t FDA-approved or legally for sale; compounded tirzepatide, not FDA-approved, is $115 a month at NexLife on the 12-month plan, or $129 month to month.
- Head to head: TRIUMPH-5, about 800 adults, through December 2026
- Retatrutide: not FDA-approved; Lilly plans to submit it in Q1 2027
- Not for sale: it can’t be compounded or legally sold

$115/mo on a 12-month plan, all-inclusive, same price at every dose
Or $129/mo month to month
Compounded tirzepatide. NexLife doesn’t offer retatrutide.
About 3 minutes of health questions · No insurance needed · Not prescribed? No charge for medication
See all 4 plans and what a year costs
| Plan | Per month | 12 months at this rate |
|---|---|---|
| 12-month Most savings | $115 | $1,380 |
| 6-month | $119 | $1,428 |
| 3-month | $125 | $1,500 |
| Month to month | $129 | $1,548 |
Month to month costs $168 more over 12 months than the 12-month plan. Month to month is billed monthly. The 3-, 6- and 12-month plans are paid upfront at checkout ($375, $714 or $1,380), and only if you’re prescribed. Plans renew until you cancel.
Price Match Guarantee†. Paying less elsewhere? We match your regular monthly price. How it works
4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 1, 2026)LegitScript-certified
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. The vial shown is an illustration. Always use the strength on your pharmacy’s label.
- Licensed U.S. providers
- LegitScript certified
- Free expedited shipping
- HSA, FSA, Affirm, Klarna, Afterpay
- 24/7 support, real people
- Filled by Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA)
Quick answer
Retatrutide vs. tirzepatide: the quick comparison
| Question | Answer |
|---|---|
| Which works better? | Not known yet: there’s no head-to-head result. TRIUMPH-5, which compares them directly, is listed to run through December 2026 |
| How much weight did people lose? | In separate trials, counting everyone who started: retatrutide 12 mg averaged 25.0% at 80 weeks (TRIUMPH-1); Zepbound 15 mg, 20.9% at 72 weeks (its label). Not a fair test |
| Side effects? | Mostly stomach-related on both. Retatrutide also caused dysesthesia, a skin-sensation change, in 12.5% on 12 mg |
| Is it FDA-approved? | Tirzepatide is, as Zepbound and Mounjaro. Retatrutide isn’t; Lilly plans to submit it to the FDA in the first quarter of 2027 |
| Can you get it now? | Retatrutide: no. The FDA says it can’t be compounded, and Lilly says it can’t be legally sold. Tirzepatide: with a prescription |
| What does it cost? | Retatrutide: no price announced. Zepbound: $299 to $449 a month at LillyDirect, by dose; the $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699 |
Trial results are Lilly’s, for its medicines in trials; compounded tirzepatide wasn’t studied. Checked November 1, 2026.
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- No head-to-head result yet: TRIUMPH-5, comparing them directly in about 800 adults, is listed to run through December 2026.
- Separate trials, counting everyone: 25.0% average loss on retatrutide 12 mg (TRIUMPH-1, 80 weeks); 20.9% on Zepbound 15 mg (SURMOUNT-1, 72 weeks).
- Two cautions: Lilly’s 28.3% headline assumes everyone stayed on treatment, and the trials studied Zepbound, not compounded tirzepatide.
- Side effects look alike, mostly stomach-related; retatrutide also caused dysesthesia, a change in skin sensation.
- Retatrutide isn’t FDA-approved and can’t be bought or compounded. Lilly plans to submit it to the FDA in Q1 2027.
- NexLife doesn’t offer retatrutide. Compounded tirzepatide at NexLife, not FDA-approved, is $115 a month on the 12-month plan.
At a glance
How are retatrutide and tirzepatide different?
Both are weekly shots from Eli Lilly. Retatrutide acts on three hormone receptors (GIP,
| Retatrutide | Tirzepatide | |
|---|---|---|
| What it acts on | Three hormone receptors: GIP, | Two hormone receptors: GIP and |
| Maker | Eli Lilly | Eli Lilly |
| How it’s taken | A weekly shot, in trials | A weekly shot |
| FDA statusas of November 1, 2026 | Investigational: not approved for any use | FDA-approved, as Zepbound for weight loss and Mounjaro for type 2 diabetes |
| How you can get it | Only in Lilly’s trials, or through a narrow expanded access program that a treating doctor applies for | With a prescription: Zepbound from LillyDirect or a pharmacy, or compounded tirzepatide, which isn’t FDA-approved |
| Self-pay price | None: it can’t be legally sold | Zepbound: $299 to $449 a month at LillyDirect, by dose ($449, from 7.5 mg, needs a refill within 45 days; otherwise $499 to $699) |
| Can it be compounded? | No. The FDA says it can’t be used in compounding | Only for one patient’s prescription, by a state-licensed 503A pharmacy, when the prescriber documents a significant difference for that patient |
Swipe the table sideways to see every column.
From Lilly’s news releases, the FDA and LillyDirect, checked November 1, 2026. Zepbound’s price needs a refill within 45 days ($499 to $699 from 7.5 mg if not); a month is 28 days. Compounded tirzepatide isn’t Zepbound. More on the rules: is compounded tirzepatide legal?
Step by step
How do you choose between retatrutide and tirzepatide today?
Right now the choice is narrow: only tirzepatide can be prescribed. These steps help you read the trials and decide what to do.
- Check what’s approved today. As of November 1, 2026, tirzepatide is FDA-approved, as Zepbound for weight loss and Mounjaro for type 2 diabetes. Retatrutide is investigational, not approved for any use; Lilly plans to submit it in the first quarter of 2027.
- Compare results like for like. In separate trials, counting everyone who started, retatrutide 12 mg averaged 25.0% weight loss at 80 weeks (TRIUMPH-1); Zepbound 15 mg, 20.9% at 72 weeks (SURMOUNT-1). Lilly’s 28.3% headline assumes everyone stayed on treatment. Compounded tirzepatide wasn’t studied.
- Watch for the head-to-head result. TRIUMPH-5 compares the two directly in about 800 adults with obesity and is listed to run through December 2026. As of Nov. 12, 2026, Lilly hadn’t announced results; its Oct. 28, 2026 release calls the trial ongoing.
- Weigh the side effects. Both are mostly stomach-related. In separate trials, nausea affected 42.4% on retatrutide 12 mg (14.8% on placebo) and 28% on Zepbound 15 mg (8% on placebo); retatrutide also caused dysesthesia, a skin-sensation change, in 12.5%.
- Don’t buy retatrutide online. The FDA says it can’t be compounded, and Lilly says it can’t be legally sold. Anything sold online as retatrutide, “research” vials included, is an unapproved product or a research chemical.
- Decide what to take now, with your provider. Zepbound is $299 to $449 a month at LillyDirect, by dose (checked Nov. 12, 2026); the $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699. Compounded tirzepatide, another option, isn’t FDA-approved. Your provider decides.
Until TRIUMPH-5 reports and the FDA decides, tirzepatide is the one you can be prescribed.
Results
Retatrutide vs. tirzepatide: which works better?
No trial has answered that yet. In separate trials, counting everyone who started, retatrutide 12 mg averaged 25.0% weight loss at 80 weeks (TRIUMPH-1, May 21, 2026). Zepbound 15 mg averaged 20.9% at 72 weeks. The trials differed, so it isn’t a fair test. These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
| Retatrutide (TRIUMPH-1) | Tirzepatide (Zepbound, SURMOUNT-1) | |
|---|---|---|
| Reported | Lilly news release, May 21, 2026 | Zepbound label (revised August 2026); The New England Journal of Medicine, 2022 |
| Who took part | 2,339 adults with obesity, or overweight with a weight-related condition, without diabetes. Average BMI 40.0 | 2,539 adults with obesity, or overweight with a weight-related condition, without diabetes. Average BMI 38 |
| Length | 80 weeks | 72 weeks |
| Doses | 4, 9 or 12 mg a week, starting at 2 mg and stepping up every 4 weeks | 5, 10 or 15 mg a week, starting at 2.5 mg and stepping up over as long as 20 weeks |
| Average loss, counting everyone who startedthe like-for-like figure | 25.0% on 12 mg 23.7% on 9 mg, 17.6% on 4 mg; placebo 3.9% | 20.9% on 15 mg 19.5% on 10 mg, 15.0% on 5 mg; placebo 3.1% |
| Average loss if everyone had stayed on treatmentLilly’s headline figure | 28.3% on 12 mg 25.9% on 9 mg, 19.0% on 4 mg; placebo 2.2% | Not on Zepbound’s label, which counts everyone who started |
Swipe the table sideways to see every column.
Not head-to-head: separate trials, with different people (average BMI 40.0 vs. 38), lengths (80 vs. 72 weeks) and top doses (12 mg vs. 15 mg). TRIUMPH-1 from Lilly’s news release of May 21, 2026; Zepbound from its prescribing information (Study 1, revised August 2026) and the SURMOUNT-1 paper. These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied. The retatrutide results are for Lilly’s medicine given in trials, not anything sold online.
Like for like: counting everyone who started, 12 mg of retatrutide averaged 25.0% at 80 weeks, and 15 mg of Zepbound 20.9% at 72 weeks. Lilly’s headline 28.3% assumes everyone stayed on treatment, so it isn’t the number to set beside Zepbound’s.
Still not a fair test. TRIUMPH-1 ran 8 weeks longer, and its people started heavier. Only TRIUMPH-5, below, compares the two medicines in the same people.
Retatrutide’s other phase 3 results, in diabetes, heart disease and knee pain, are on our retatrutide guide.
Two ways to count
Why can’t you compare retatrutide’s 28.3% with Zepbound’s 20.9%?
Because they count different things. Lilly’s headline 28.3% (TRIUMPH-1, May 21, 2026) assumes everyone stayed on retatrutide. Zepbound’s 20.9% counts everyone who started, including people who stopped. Counted the same way, retatrutide 12 mg was 25.0%, so the like-for-like gap is 25.0% vs. 20.9%. These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
Counting everyone who started
The “treatment-regimen” estimand includes every person randomized, even people who stopped the medicine. TRIUMPH-1: 25.0% on 12 mg of retatrutide. Zepbound’s trial was reported this way: 20.9% on 15 mg.
As if everyone had stayed on
The “efficacy” estimand estimates the result had everyone kept taking the medicine, so it runs higher: 28.3% on 12 mg of retatrutide. It’s the figure in Lilly’s headline.
Reading a headline? Check two things before you compare: which way the loss was counted, and how many weeks the trial ran.
Definitions from Lilly’s TRIUMPH-1 release (May 21, 2026) and the SURMOUNT-1 paper (The New England Journal of Medicine, 2022), whose treatment-regimen estimand gives the 20.9% on Zepbound’s label. These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
Head to head
TRIUMPH-5: when will retatrutide vs. tirzepatide results come out?
Not yet. TRIUMPH-5 compares the two directly in about 800 adults with obesity, measuring weight change at week 80. Lilly’s listing runs through December 2026, and ClinicalTrials.gov estimates its primary completion in November 2026. As of Nov. 12, 2026, Lilly hadn’t announced results; its Oct. 28, 2026 release calls the trial ongoing.
| What it compares | Retatrutide and tirzepatide, double-blind, with no placebo group |
|---|---|
| Who’s in it | About 800 adults with obesity. Enrollment is complete, Lilly’s listing says |
| What it measures | The percent change in body weight at week 80 |
| Dates | November 1, 2024 to December 2026 on Lilly’s listing. ClinicalTrials.gov estimates its primary completion in November 2026 |
| Registry number | NCT06662383 |
When will results come? Lilly hasn’t said. Until it reports them, the trials above can’t tell you which medicine works better.
Side effects
Retatrutide vs. tirzepatide side effects: how do they compare?
They look alike: mostly nausea, diarrhea, constipation and vomiting. In separate trials, nausea affected 42.4% on retatrutide 12 mg (TRIUMPH-1, May 21, 2026) and 28% on Zepbound 15 mg (its label). Retatrutide also caused dysesthesia, a skin-sensation change, in 12.5%. These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
| Side effect | Retatrutide 12 mg (TRIUMPH-1) | Zepbound 15 mg (label) |
|---|---|---|
| Nausea | 42.4% (placebo 14.8%) | 28% (placebo 8%) |
| Diarrhea | 32.0% (placebo 13.5%) | 23% (placebo 8%) |
| Constipation | 26.1% (placebo 10.9%) | 11% (placebo 5%) |
| Vomiting | 25.3% (placebo 4.8%) | 13% (placebo 2%) |
| Dysesthesiaa change in skin sensation | 12.5% (placebo 0.9%) | 0.4% (placebo 0.1%) |
| Stopped because of side effects | 11.3% (placebo 4.9%) | 6.7% (placebo 3.4%) |
Swipe the table sideways to see every column.
Not head-to-head. Retatrutide: TRIUMPH-1, 80 weeks, adults without diabetes (Lilly, May 21, 2026). Zepbound: its prescribing information (revised August 2026), Studies 1 and 2 pooled, 72 weeks; Study 2 enrolled people with type 2 diabetes. These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
Lower doses, fewer stops. On 4 mg of retatrutide, 4.1% stopped because of side effects, against 4.9% on placebo. Lilly says dysesthesia was mostly mild to moderate and usually resolved during treatment.
What to expect on tirzepatide, and what helps: tirzepatide side effects.
Head-to-head trials
Has retatrutide been tested head to head against another GLP-1 yet?
Once, and not against tirzepatide. On Oct. 28, 2026, Lilly reported TRANSCEND-T2D-2, retatrutide against Ozempic 2 mg in adults with type 2 diabetes. TRIUMPH-5, retatrutide against tirzepatide, is still running, Lilly said the same day.
| Trial | Compared with | Who and how long | What Lilly reported |
|---|---|---|---|
| TRANSCEND-T2D-2 | Ozempic (semaglutide) 2 mg, its highest approved dose | Adults with type 2 diabetes; 80 weeks | A1C fell 2.2 points on retatrutide 9 mg or 12 mg vs. 1.8 on Ozempic, from 8.3%. Weight fell 19.5% (9 mg) and 20.9% (12 mg) vs. 9.4%. Both assume everyone stayed on treatment |
| TRIUMPH-5 (NCT06662383) | Tirzepatide | About 800 adults with obesity; weight change at week 80 | No results yet. Lilly calls it ongoing; its listing runs through December 2026 |
Lilly’s release of Oct. 28, 2026 and its TRIUMPH-5 listing, read Nov. 12, 2026. These trials studied Lilly’s and Novo Nordisk’s medicines; compounded tirzepatide wasn’t studied.
What it tells you about tirzepatide: nothing yet. Beating Ozempic 2 mg doesn’t show how retatrutide compares with tirzepatide, which also beat a semaglutide dose in its own diabetes trial, SURPASS-2 (2021). Only TRIUMPH-5 tests the two in the same people.
Approval and price: Lilly has said it plans to submit retatrutide to the FDA in the first quarter of 2027, and it hasn’t announced a price. The timeline, Lilly’s expanded access program and how to look for a trial are on our retatrutide guide. For comparison, Zepbound is $299 to $449 a month at LillyDirect, by dose (checked Nov. 12, 2026); the $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699. Every Zepbound price.
Buying it
Can you buy retatrutide now?
No. Retatrutide isn’t FDA-approved, the FDA says it can’t be used in compounding (page read Nov. 12, 2026), and Lilly calls it an investigational molecule that can’t be legally sold (Sept. 29, 2026). So the choice you can act on today is between forms of tirzepatide.
“Retatrutide and cagrilintide cannot be used in compounding under federal law.”
Anything sold online as retatrutide, “compounded” or “research” vials included, is an unapproved product of unknown quality, the FDA says. NexLife doesn’t offer retatrutide. Trials and Lilly’s expanded access program: our retatrutide guide. Why “research use” vials are risky: research peptides vs. prescribed
Available now
What can you take now instead of retatrutide?
Retatrutide isn’t an option yet. You can be prescribed Zepbound, Lilly’s FDA-approved tirzepatide, at $299 to $449 a month on LillyDirect (checked Nov. 12, 2026), or compounded tirzepatide or semaglutide, which aren’t FDA-approved. Zepbound’s $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699. How the two kinds differ: compounded tirzepatide vs. Zepbound. Every option while retatrutide is in trials: our retatrutide guide.
Zepbound (tirzepatide)
Lilly’s FDA-approved weekly shot: $299 to $449 a month at LillyDirect, by dose; the $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699.
Compounded tirzepatide or semaglutide
Prepared by a state-licensed 503A pharmacy for one patient’s prescription. Neither is FDA-approved, neither is retatrutide, and neither was studied in the trials on this page.
At NexLife, compounded tirzepatide is $115 a month on the 12-month plan, or $129 month to month, and compounded semaglutide is $95 a month on the 12-month plan, or $109 month to month. The price is the same at every dose, with no membership fee, and a licensed provider decides if one is right for you.
Other FDA-approved options include Wegovy and Foundayo, Lilly’s daily pill.
In their words
What do Zepbound’s label and the FDA say about tirzepatide?
Two lines on the medicine you can be prescribed now.
Tirzepatide acts on two hormone receptors, and retatrutide, still investigational, adds a third, glucagon; Zepbound’s label says:
“Tirzepatide is a GIP receptor and GLP-1 receptor agonist.”
Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, Mechanism of Action (revised August 2026)
If you’re weighing compounded tirzepatide, which isn’t FDA-approved, here is the FDA’s recommendation:
“Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.”
U.S. Food and Drug Administration, FDA’s concerns with unapproved GLP-1 drugs used for weight loss, “FDA recommendations for health care professionals and patients”
Vial math
How many units is your tirzepatide dose?
It depends on your vial’s strength. Here are the label’s doses at one example strength, with the math to check your own.
| Dose | mL at 25 mg/mL | Units (U-100) | On the label |
|---|---|---|---|
| 2.5 mg | 0.1 mL | 10 units | Starting dose, for 4 weeks |
| 5 mg | 0.2 mL | 20 units | A maintenance dose |
| 7.5 mg | 0.3 mL | 30 units | A step up |
| 10 mg | 0.4 mL | 40 units | A maintenance dose |
| 12.5 mg | 0.5 mL | 50 units | A step up |
| 15 mg | 0.6 mL | 60 units | The maximum, and a maintenance dose |
The math: mL = dose ÷ strength (mg per mL), and units = mL × 100. At 25 mg/mL, 10 mg is 10 ÷ 25 = 0.4 mL, or 40 units.
25 mg per mL is an example only: it’s the strength of the 15 mg multi-dose vial on Zepbound’s label (15 mg per 0.6 mL). Read the strength on your own vial’s label; your provider sets your dose, in steps at least 4 weeks apart. Every step: the tirzepatide dosage chart. Or enter your own vial’s strength in the tirzepatide dosage calculator.
What does NexLife cost?
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†
GIP + 12-month plan $115/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan; $129/mo month to month.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication

12-month plan $95/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms
The NexLife Price Match Guarantee†
Paying less elsewhere?
Keep your price. Upgrade your care.
Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.
- 1Send a receipt from the last 60 days
- 2A NexLife provider reviews your prescription
- 3Pay your matched price, at every dose
Locked while your plan is activeSame price at every doseNo membership fee
†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.
Retatrutide vs. tirzepatide: your questions
Fair questions about NexLife
- Will my price go up with my dose?
- No. You pay the same at every dose.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
Is retatrutide better than tirzepatide?
No head-to-head result yet: Lilly’s TRIUMPH-5 trial of retatrutide against tirzepatide runs through December 2026, and retatrutide isn’t FDA-approved or legally for sale. In separate trials, people lost more weight on retatrutide, but those trials differed in length, people and how weight loss was counted. Only TRIUMPH-5’s results can show which works better.
How much weight do people lose on retatrutide vs. Zepbound?
In separate trials, counting everyone who started, retatrutide 12 mg averaged 25.0% at 80 weeks (TRIUMPH-1, Lilly, May 21, 2026) and Zepbound 15 mg 20.9% at 72 weeks (its label). Lilly’s headline 28.3% assumes everyone stayed on treatment. These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
Does retatrutide have more side effects than tirzepatide?
Separate trials can’t say for sure: no trial has compared them directly yet. The types look alike, mostly stomach-related. On retatrutide 12 mg, 42.4% had nausea and 11.3% stopped because of side effects (TRIUMPH-1); on Zepbound 15 mg, 28% and 6.7% (its label). Retatrutide also caused dysesthesia, a skin-sensation change, in 12.5%.
What is TRIUMPH-5?
It’s Lilly’s phase 3 trial comparing retatrutide directly with tirzepatide, double-blind and with no placebo group, in about 800 adults with obesity. It measures the percent change in body weight at week 80 (NCT06662383). Lilly’s listing runs from Nov. 1, 2024, to December 2026, and Lilly hadn’t announced results as of Nov. 12, 2026.
Can I join the retatrutide vs. tirzepatide trial?
Not TRIUMPH-5: its enrollment is complete, Lilly’s listing says, with about 800 adults in it. It’s listed to run through December 2026 (NCT06662383). Other retatrutide trials are listed on ClinicalTrials.gov, and your doctor can tell you whether one fits you. Lilly’s expanded access program is narrow, and a treating doctor applies for it.
Can I switch from tirzepatide to retatrutide?
Not yet. As of November 1, 2026, retatrutide isn’t FDA-approved and Lilly says it can’t be legally sold, so no prescription can switch you to it. Lilly’s trials and its narrow expanded access program (NCT07629401) are the only routes, and a treating doctor has to request access. Whether you stay on tirzepatide is your provider’s call.
Has retatrutide been compared head to head with a GLP-1 yet?
Once, with Ozempic, not tirzepatide. In TRANSCEND-T2D-2, reported by Lilly on Oct. 28, 2026, adults with type 2 diabetes lowered A1C 2.2 points on retatrutide 9 or 12 mg vs. 1.8 on Ozempic 2 mg, and lost 19.5% to 20.9% of their weight vs. 9.4% over 80 weeks, assuming everyone stayed on treatment. TRIUMPH-5, against tirzepatide, is ongoing.
How do retatrutide and tirzepatide work differently?
Retatrutide acts on three hormone receptors, GIP, GLP-1 and glucagon; tirzepatide acts on two, GIP and GLP-1. Both are weekly shots from Eli Lilly. Only tirzepatide is FDA-approved, as Zepbound for weight loss and Mounjaro for type 2 diabetes. Retatrutide is investigational, and the FDA says it can’t be used in compounding.
Is “research” retatrutide safe to inject?
There’s no way to know what’s in it. It isn’t approved or made for people, and the FDA says products labeled “for research purposes” or “not for human consumption” are of unknown quality and may be harmful. It urges consumers not to buy them. NexLife doesn’t offer retatrutide.
Can tirzepatide be compounded?
Yes, but only for one patient’s prescription, by a state-licensed 503A pharmacy, when the prescriber documents a significant difference for that patient. Compounded tirzepatide isn’t FDA-approved. Retatrutide can’t be compounded at all: the FDA says it can’t be used in compounding under federal law.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. The FDA warned on Nov. 9, 2026, that GLP-1 medicines may raise the risk of NAION, a rare eye condition that can cause sudden vision loss in one eye; call your provider right away if that happens (FDA). Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
Who wrote and medically reviewed this page?
Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.
Lilly’s Oct. 28, 2026, release, its TRIUMPH-5 listing, the FDA’s statement and LillyDirect’s prices checked Nov. 12, 2026; Lilly’s earlier releases and the Zepbound label, Nov. 1, 2026; the other registry entries, Oct. 25, 2026.
- How we checked. Every result here comes from Lilly’s news releases, the Zepbound prescribing information and the SURMOUNT-1 paper, read on November 1, 2026, and the trial registries, checked October 25, 2026. We read Lilly’s Oct. 28, 2026, release and re-checked the TRIUMPH-5 listing, the FDA’s statement on compounding and LillyDirect’s prices on Nov. 12, 2026. Each number comes with its trial, its length and how it was counted, and we don’t forecast approval dates or prices.
- Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email hello@nexlife.us and we’ll fix it.
- How we work. How we review programs · GLP-1 price index · Is NexLife legit? · States NexLife serves
Paying less elsewhere? We match it.†
Want something you can start now?
Start with a 3-minute online check. A licensed provider decides if compounded tirzepatide is right for you: $115 a month on the 12-month plan, or $129 month to month, at every dose.
4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 1, 2026) · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
- 1Tell us about you
Start online with your health history.
- 2A licensed provider decides
Online, following your state’s rules. You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.
Sources
- Eli Lilly: Retatrutide delivered powerful weight loss in pivotal phase 3 obesity trial, TRIUMPH-1 (May 21, 2026). Read November 1, 2026.
- Eli Lilly: retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic’s highest approved dose in head-to-head trial (TRANSCEND-T2D-2; TRIUMPH-5 ongoing) (Oct. 28, 2026). Read Nov. 12, 2026.
- Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). The New England Journal of Medicine, 2021.
- Eli Lilly: Retatrutide successful in two additional phase 3 obesity trials, TRIUMPH-2 and TRIUMPH-3 (July 23, 2026). Read November 1, 2026.
- Eli Lilly: Retatrutide delivered substantial weight loss and A1C reduction, TRIUMPH-2 in The Lancet (September 29, 2026). Read November 1, 2026.
- Eli Lilly clinical trials: TRIUMPH-5, retatrutide compared with tirzepatide in adults with obesity. Checked October 25, 2026.
- ClinicalTrials.gov: NCT06662383 (TRIUMPH-5). Checked October 25, 2026.
- ClinicalTrials.gov: NCT07629401, pre-approval expanded access of retatrutide. Checked October 25, 2026.
- Lilly Medical: Is there an expanded access program for retatrutide? (last reviewed August 26, 2026). Read November 1, 2026.
- Zepbound (tirzepatide) prescribing information, Eli Lilly, revised August 2026. Read November 1, 2026.
- SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-216. Abstract read November 1, 2026.
- FDA: Concerns with unapproved
GLP-1 drugs used for weight loss (updated October 1, 2026). Read Nov. 12, 2026. - LillyDirect: Zepbound self-pay prices. Checked Nov. 12, 2026.
- NexLife: pricing, every plan.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
- U.S. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. April 1, 2026: Foundayo (orforglipron).